Chinese biotech company, BeiGene (NASDAQ: BGNE) sunk in pre-market trading at the time of publishing on Thursday after a Bloomberg Law report that AbbVie (ABBV) filed a lawsuit in the U.S. District Court for the District of Delaware against BeiGene that accuses the company of a patent violation. ABBV has stated that BeiGene’s Brukinsa infringes on a patent covering ABBV’s blood cancer therapy Imbruvica.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Imbruvica is marketed by AbbVie’s Pharmacyclics unit and Johnson & Johnson’s (JNJ) Janssen Biotech.
Analysts are bullish about BGNE stock with a Strong Buy consensus rating based on four Buys and one Hold.